Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biobank aims to unlock secrets of liver and pancreatic cancers

NCT ID NCT07344116

Knowledge-focused Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will create a biobank by collecting blood, tissue, and bile samples from 300 adults with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments or extra procedures are involved—samples are taken during routine care. The goal is to provide a long-term resource for researchers to better understand these diseases and develop future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients receiving care at the Second Affiliated Hospital of Zhejiang University School of Medicine who are diagnosed with hepatobiliary or pancreatic malignant tumors, as well as patients with benign hepatobiliary or pancreatic diseases. Selected healthy adult volunteers may also be included as controls. Participants are enrolled without altering routine medical care, and biological specimens and related clinical data are collected for biobanking and future research purposes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Patients diagnosed with hepatobiliary or pancreatic malignant tumors, including but not limited to hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, and pancreatic cancer; or patients with benign hepatobiliary or pancreatic diseases; or selected healthy volunteers. * Receiving medical care or health evaluation at the Second Affiliated Hospital of Zhejiang University School of Medicine. * Able and willing to provide written informed consent, unless waived or exempted by the institutional ethics committee for retrospective samples. * Willing to allow collection and storage of biological specimens and related clinical data for research purposes. Exclusion Criteria: * Age younger than 18 years. * Unable to provide informed consent and without a legally authorized representative. * Presence of conditions that, in the opinion of the investigators, make participation inappropriate or infeasible. * Refusal to allow the collection or use of biological specimens or clinical data for research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma gallbladder cancer hepatocellular carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholangiocarcinoma Hepotacellular carcinoma Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.